Postlewait Lauren M, Ethun Cecilia G, Le Nina, Pawlik Timothy M, Buettner Stefan, Poultsides George, Tran Thuy, Idrees Kamran, Isom Chelsea A, Fields Ryan C, Krasnick Bradley, Weber Sharon M, Salem Ahmed, Martin Robert C G, Scoggins Charles, Shen Perry, Mogal Harveshp D, Schmidt Carl, Beal Eliza, Hatzaras Ioannis, Vitiello Gerardo, Cardona Kenneth, Maithel Shishir K
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Division of Surgical Oncology, Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA.
HPB (Oxford). 2016 Oct;18(10):793-799. doi: 10.1016/j.hpb.2016.07.009. Epub 2016 Aug 9.
Seventh AJCC distal cholangiocarcinoma T-stage classification inadequately separates patients by survival. This retrospective study aimed to define a novel T-stage system to better stratify patients after resection.
Curative-intent pancreaticoduodenectomies for distal cholangiocarcinoma (1/2000-5/2015) at 10 US institutions were included. Relationships between tumor characteristics and overall survival (OS) were assessed and incorporated into a novel T-stage classification.
176 patients (median follow-up: 24mo) were included. Current AJCC T-stage was not associated with OS (T1: 23mo, T2: 20mo, T3: 25mo, T4: 12mo; p = 0.355). Tumor size ≥3 cm and presence of lymphovascular invasion (LVI) were associated with decreased OS on univariate and multivariable analyses. Patients were stratified into 3 groups [T1: size <3 cm and (-)LVI (n = 69; 39.2%); T2: size ≥3 cm and (-)LVI or size <3 cm and (+)LVI (n = 82; 46.6%); and T3: size ≥3 cm and (+)LVI (n = 25; 14.2%)]. Each progressive proposed T-stage was associated with decreased median OS (T1: 35mo; T2: 20mo; T3: 8mo; p = 0.002).
Current AJCC distal cholangiocarcinoma T-stage does not adequately stratify patients by survival. This proposed T-stage classification, based on tumor size and LVI, better differentiates patient outcomes after resection and could be considered for incorporation into the next AJCC distal cholangiocarcinoma staging system.
美国癌症联合委员会(AJCC)第七版远端胆管癌T分期系统在依据生存情况对患者进行区分方面存在不足。本回顾性研究旨在定义一种新的T分期系统,以在切除术后更好地对患者进行分层。
纳入美国10家机构在2000年1月至2015年5月期间因远端胆管癌接受根治性胰十二指肠切除术的患者。评估肿瘤特征与总生存期(OS)之间的关系,并将其纳入一种新的T分期分类。
共纳入176例患者(中位随访时间:24个月)。当前的AJCC T分期与总生存期无关(T1期:23个月,T2期:20个月,T3期:25个月,T4期:12个月;p = 0.355)。在单因素和多因素分析中,肿瘤大小≥3 cm和存在淋巴管侵犯(LVI)与总生存期降低相关。患者被分为3组[T1期:肿瘤大小<3 cm且无LVI(n = 69;39.2%);T2期:肿瘤大小≥3 cm且无LVI或肿瘤大小<3 cm且有LVI(n = 82;46.6%);T3期:肿瘤大小≥3 cm且有LVI(n = (此处原文有误,应为25;14.2%)]。每个递进的拟议T分期均与中位总生存期降低相关(T1期:35个月;T2期:20个月;T3期:8个月;p = 0.002)。
当前的AJCC远端胆管癌T分期在依据生存情况对患者进行分层方面不够充分。这种基于肿瘤大小和LVI的拟议T分期分类能更好地区分切除术后患者的预后,可考虑纳入下一版AJCC远端胆管癌分期系统。